Abul K. Abbas, M.D., Joins Megabios' Scientific Advisory Board.BURLINGAME, Calif.--(BW HealthWire)--Feb. 12, 1997--Benjamin F. McGraw III, President and Chief Executive Officer of Megabios Corp., announced today that Abul K. Abbas, M.D. has been appointed to its Scientific Advisory Board. Dr. Abbas is Head of the Immunology Research Division, in the Department of Pathology at Brigham and Women's Hospital Brigham and Women's Hospital (BWH) is a hospital in the Longwood Area of the Boston, Massachusetts neighborhood of Mission Hill. With Massachusetts General Hospital, it is one of the two founding members of Partners HealthCare. , and Professor of Pathology, at Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. . He is an active member of the American Association American Association refers to one of the following professional baseball leagues:
"The specific background and experience that Dr. Abbas brings in the field of immunology is critical to the successful development of gene-based products for immunotherapy. We are very pleased that Dr. Abbas will be advising us in the development of this interesting class of products," noted McGraw. Megabios Corp. develops gene-based therapeutics in collaboration with pharmaceutical and biotechnology companies using its proprietary gene delivery technology and preclinical development expertise. Megabios is focused on providing fully integrated preclinical development support required to convert putative therapeutic genes into gene-based therapies that share characteristics of traditional pharmaceuticals. To date, Megabios has established corporate partnerships with GlaxoWellcome plc in the field of cystic fibrosis cystic fibrosis (sĭs`tĭk fībrō`sĭs), inherited disorder of the exocrine glands (see gland), affecting children and young people; median survival is 25 years in females and 30 years in males. therapy and Pfizer Inc in the field of cancer therapy via angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. inhibition. CONTACT: Megabios Corporation Patrick Enright, 415/697-1900, ext. 214 enright@megabios.com or Burns McClellan Jonathan Nugent (investor inquiries), 212/505-1919 Justin Jackson (media inquiries), 212/505-1919 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion